1. Home
  2. CCHH vs SGMT Comparison

CCHH vs SGMT Comparison

Compare CCHH & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CCHH

CCH Holdings Ltd Ordinary Shares

N/A

Current Price

$14.09

Market Cap

203.1M

Sector

N/A

ML Signal

N/A

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

HOLD

Current Price

$6.28

Market Cap

238.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCHH
SGMT
Founded
2015
2006
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
203.1M
238.7M
IPO Year
2025
2023

Fundamental Metrics

Financial Performance
Metric
CCHH
SGMT
Price
$14.09
$6.28
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$29.75
AVG Volume (30 Days)
740.6K
543.4K
Earning Date
12-19-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.03
N/A
Revenue
$8,915,344.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$273.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.49
$1.73
52 Week High
$14.40
$11.41

Technical Indicators

Market Signals
Indicator
CCHH
SGMT
Relative Strength Index (RSI) N/A 39.68
Support Level N/A $5.95
Resistance Level N/A $6.55
Average True Range (ATR) 0.00 0.45
MACD 0.00 -0.09
Stochastic Oscillator 0.00 16.36

Price Performance

Historical Comparison
CCHH
SGMT

About CCHH CCH Holdings Ltd Ordinary Shares

CCH Holdings Ltd operates a hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot, mainly under two brand, namely Chicken Claypot House and Zi Wei Yuan, owned by the wholly owned subsidiaries of the Company. The Company conducts its operations through its wholly owned subsidiaries in Malaysia and is engaged as a restaurant operator, licensor and loyalty owner, and general trader. Currently, the Group has developed a restaurant chain including approximately 15 company-owned restaurant outlets, 13 franchised restaurant outlets in Malaysia, and 4 franchised restaurant outlets outside Malaysia.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: